Alvotech Secures Financing Facilities of Approximately $136 Million
- Existing senior bonds upsized by $70 million with additional investment from a consortium of institutional investors
- Alvotech acquires the Reykjavik manufacturing facility, previously utilized under a long-term lease agreement, and secures approximately $16 million, at current exchange rates, in gross loan proceeds through refinancing of secured loan facility
- Alvotech secures $50 million in financing in the form of an unsecured subordinated loan facility from Alvogen
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financing facilities securing gross proceeds of approximately $136 million, at current exchange rates. "These financing facilities are designed to provide flexibility and additional resources for advancing the company's growing biosimilar pipeline,” said Joel Morales, Chief Financial Officer of Alvotech.
Alvotech has upsized its existing senior bonds by $70 million (“First Lien Facility”) with additional investment from Farallon Capital Management, Sculptor Capital Management, Oaktree Capital Management, Lodbrok Capital, and Morgan Stanley. As part of the expanded First Lien Facility, bondholders have the right to procure warrants representing up to 2.5% of Alvotech’s ordinary share capital unless Alvotech raises additional capital in accordance with the terms of the First Lien Facility.
Separately, Alvotech has secured from Alvogen, a major shareholder, an additional $50 million in the form of an unsecured subordinated loan (“Alvogen Facility”), which also provides the right to procure warrants representing up to 4.0% of Alvotech’s ordinary share capital unless Alvotech does not utilize the proceeds of the Alvogen Facility and replaces the Alvogen Facility with new financing, under certain commercial terms, by December 15, 2022.
Ownership of the previously leased manufacturing facility will be transferred to Alvotech from a subsidiary of Aztiq, a major shareholder, in exchange for an unsecured subordinated convertible bond in the principal amount of $80 million. In connection with the acquisition of the manufacturing facility in Reykjavik, Alvotech entered into a secured loan agreement with Landsbankinn hf. to provide for approximately $16 million, at current exchange rates, in gross loan proceeds to Alvotech.
Further information with respect to additional financing arrangements will be set forth in the report on Form 6-K that will be filed by the Company with the Securities and Exchange Commission, and made available on https://investors.alvotech.com/publicfilings, attached to which as exhibits will be the agreements described herein. The contents of this press release, and the description of the financing arrangements reflected herein, are qualified in their entirety by the definitive form of such agreements.
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility
for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding capitalization through equity or debt financing, future growth, results of operations, reductions in lease obligations and cash savings, cash runway, utilization of the backstop financing with Alvogen, performance, future capital and other expenditures including the development of critical infrastructure for the global healthcare markets, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “aim” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against Alvotech or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech; (2) the ability to close the financing facilities and meet the requirements under those arrangements; (3) the ability to maintain stock exchange listing standards; (4) changes in applicable laws or regulations; (5) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (6) Alvotech’s estimates of expenses and profitability; (7) Alvotech’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (8) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the potential impact of the ongoing COVID-19 pandemic on the FDA’s review timelines, including its ability to complete timely inspection of manufacturing sites; (18) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Company’s business, financial position, strategy and anticipated milestones; and (19) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.
Alvotech Investor Relations and Global Communications
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iceland Seafood International hf completes auction of bills28.11.2022 22:45:53 CET | Press release
Iceland Seafood International hf. has concluded an offering of 6-month bills in the new series ICESEA 23 0602. Total offers for bills in the auction amounted to ISK 1.000 million which were all accepted, at a simple rate of 9.50%. The bills are scheduled to be admitted to trading on Nasdaq Iceland in the coming weeks.
Brookfield to Present at the Goldman Sachs 2022 US Financial Services Conference28.11.2022 22:01:00 CET | Press release
BROOKFIELD, NEWS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) today announced that Bruce Flatt, Chief Executive Officer, is scheduled to present at the Goldman Sachs US Financial Services Conference on Wednesday, December 7, 2022, at 1:40pm ET. A live webcast will be available on the Brookfield website at https://bam.brookfield.com/news-events/events. For those unable to join the live webcast, a recording will be available on Brookfield’s website shortly after the event. About Brookfield Brookfield (NYSE: BAM, TSX: BAM.A) is a leading global alternative asset manager with over $750 billion of assets under management across real estate, infrastructure, renewable power and transition, private equity and credit. Brookfield owns and operates long-life assets and businesses, many of which form the backbone of the global economy. Utilizing its global reach, access to large-scale capital and operational expertise, Brookfield offers a range of alt
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US28.11.2022 22:00:00 CET | Press release
New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensa
EYES ON IRAN ART ACTIVATION FACES THE U.N. IN NEW YORK28.11.2022 21:04:15 CET | Press release
AN EVENT MARKED THE OPENING FEATURING HILLARY RODHAM CLINTON, GISSOU NIA,SHEIDA SOLEIMANI, SHIRIN NESHAT with SPECIAL PERFORMANCE BY JON BATISTE NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Iranian artists Sheida Soleimani, Aphrodite Désirée Navab, Z, Icy and Sot, Shirin Neshat, Mahvash Mostala, Sepideh Mehraban, and Shirin Towfiq, alongside artists Hank Willis Thomas and JR, activate New York’s FDR Four Freedoms State Park with a provocative multi-day and multi-media art installation facing the United Nations entitled Eyes on Iran, November 28, 2022 - January 1, 2023. Timed for the U.N. initiative, 16 Days of Activism Against Gender-Based Violence, the installations are focused on the power of collective sight, with eyes facing the U.N., signifying the world’s eyes on Iran. 'Eyes in the Sky' flying billboards featuring artworks by Thomas and Mostala will fly on December 3 in New York City and on November 28 and 30 in Miami. An interactive installation by artist JR will take place on
PRESS RELEASE: BIGBEN: 2022-23 HALF-YEAR RESULTS28.11.2022 18:09:56 CET | Press release
Press release Lesquin, 28 November 2022 18:00hrs 2022-23 HALF-YEAR RESULTS UP 138.5 M€ SALES (+11.6%)11.8 M€ CURRENT OPERATING RESULT (+19.6%)7.6 M€ NET RESULT (+9.6%) STRONG GROWTH AMBITION REITERATED FOR FY2023-24 CONTINUATION OF THE GAMES PUBLISHING MOMENTIUMENCOURAGING OUTLOOK FOR THE AUDIOVIDEO/TELCO BUSINESS BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its audited consolidated results for 1st Half Year 2022-23 (from April 1, 2022 to September 30, 2022) as approved by its Board of directors on 28 November 2022. Consolidated in M€ - IFRS09/202209/2021 ChangeSales138.5124.2+11.6%Gross margin (1) In % of Sales EBITDA(2) In % of Sales 64.8 46.8% 28.3 20.4% 51.4 41.4% 24.6 19.8%+26.0% +15.2%Current operating income EBITA In % of Sales Non recurrent items 11.8 8.5% (1.4)9.9 8.0% (5.8) +19.6% Operating income In % of Sales 10.5 7.6%4.1 3.3%+153.6%Financial result(0.3)4.8 Earnings before tax In % of Sales 10.2 7.4%9.0 7.2%+13.5%Tax(2.6)(2.0)Net result for the period In % of Sales